Amphotricine gel for cutaneous leishmaniasis treatment
Phase 3
Recruiting
- Conditions
- cutaneous leishmaniasis.Cutaneous leishmaniasisB55.1
- Registration Number
- IRCT20221205056717N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Cutaneous leishmaniasis infection confirmed by PCR
Written informed consent to participate in the study after being explained about the study procedures and possible complications
Not having a history of drug reaction to the studied treatments
Exclusion Criteria
History of immunodeficiency
Pregnancy and breastfeeding
Sign or symptoms of malnutrition
History of cardiac, renal or hepatic diseases
Severe allergic reaction or adverse effects due to Glucantim or Amphotricine that interfere with the treatment
Violating study protocol
Refusing treatment during follow up or lost contact
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The size of the lesion. Timepoint: Weekly follow-up up to a maximum of 12 weeks. Method of measurement: ruler.
- Secondary Outcome Measures
Name Time Method The size of scar. Timepoint: Weekly follow-up up to a maximum of 12 weeks. Method of measurement: Ruler.